| CEUEX | REREX | CEUEX / REREX | |
| Total Expense Ratio | 1.09 | 0.82 | 133% |
| Annual Report Gross Expense Ratio | 1.09 | 0.82 | 133% |
| Fund Existence | 25 years | 24 years | - |
| Gain YTD | 5.115 | 5.367 | 95% |
| Front Load | N/A | N/A | - |
| Min. Initial Investment | 250 | 250 | 100% |
| Min. Initial Investment IRA | N/A | N/A | - |
| Net Assets | 140B | 140B | 100% |
| Annual Yield % from dividends | 2.39 | 2.55 | 94% |
| Returns for 1 year | 1.56 | 1.90 | 82% |
| Returns for 3 years | 25.94 | 27.08 | 96% |
| Returns for 5 years | -5.68 | -5.42 | 105% |
| Returns for 10 years | 47.60 | 43.36 | 110% |
| 1 Day | |||
|---|---|---|---|
| MFs / NAME | Price $ | Chg $ | Chg % |
| IYCEX | 18.36 | 0.11 | +0.60% |
| Nomura Core Equity Fund Class R | |||
| VITNX | 125.93 | N/A | N/A |
| Vanguard MStar Inst Ttl Stk Mkt IdxInstl | |||
| FTDZX | 208.33 | N/A | N/A |
| Franklin Biotechnology Discovery Adv | |||
| JFCAX | 36.50 | N/A | N/A |
| JHancock Fundamental All Cap Core A | |||
| CSDGX | 16.27 | N/A | N/A |
| Copeland SMID Cap Dividend Growth A | |||